GlassScriptPhysician profile
Anna W Jones
NPI 1902541659
$2,844.69
in general payments reported to CMS, 2019-2025
23 companies · $1,923 in 2025
The $1,923 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $166 · 2024: $755 · 2025: $1,923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,768 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,767.70 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $376.16 | 2024-2025 | Tremfya |
| Abbvie INC. | $341.26 | 2024-2025 | |
| Madrigal Pharmaceuticals | $311.55 | 2024-2025 | Rezdiffra |
| Pfizer INC. | $223.45 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.20 | 2024-2025 | Xifaxan |
| Gilead Sciences, INC. | $178.82 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $175.29 | 2025 | Zenpep |
| Qol Medical, LLC | $167.68 | 2024-2025 | Sucraid, Sucraid |
| Inari Medical, INC. | $166.23 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Intercept Pharmaceuticals, INC. | $153.85 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.45 | 2024-2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $82.05 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $64.12 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $63.04 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $39.85 | 2025 | Voquezna |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $33.43 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $32.39 | 2025 | Iqirvo |
| Evoke Pharma, INC. | $29.38 | 2025 | |
| Organon LLC | $27.61 | 2025 | Hadlima |
| Shield Therapeutics INC | $25.43 | 2025 | |
| Daiichi Sankyo INC. | $24.09 | 2025 | Injectafer |
| Merck Sharp & Dohme LLC | $20.00 | 2024 | Dificid |
| Mallinckrodt Hospital Products INC. | $15.36 | 2025 | Terlivaz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.